When I received an offer from Boston Scientific to buy my company for $275 million, it was a moment of disbelief after years of struggle and rejection.

I worked as an engineer at Abbott Vascular and a smaller startup, but I felt an urge to start my own company at 24, driven by my past health experiences.

After selling my company, I was invited to be the first healthcare and biotech partner at Y Combinator, where I could share my story and help other founders.

After experiencing a health scare in high school, I realized how antiquated women's health care was, which inspired me to start a company focused on women's health.

I was a happy surgeon, but after a two-year break in Boston working at Dana Farber Cancer Institute, I realized entrepreneurship looked really appealing.

After raising our seed round, we went on to raise about $20 million more in venture capital, taking our device through prototype stages and clinical studies, ultimately achieving FDA clearance.

I aimed to build my company to deliver a product that could quickly provide answers for women with complex cysts, helping them avoid unnecessary interventions if they weren't cancerous.

I raised 1.6 million and obsessively built the company for three years, achieving 8.4X growth in one year, which led to a position where I didn't need the money when I went to raise again.

I realized that prioritizing family was essential, especially when I had young children, which influenced my decision to sell part of the business for $100 million.